*1 Case 1:20-md-02930-RGA Document 1512 Filed 08/23/24 Page 1 of 2 PageID #: 52473
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) In re Entresto (Sacubitril/Valsartan) Patent ) MDL No. 20-2930-RGA Litigation )
) NOVARTIS PHARMACEUTICALS )
CORPORATION, )
) C.A. No. 19-1979-RGA Plaintiff, ) ) v. ) )
TORRENT PHARMA INC., TORRENT ) PHARMACEUTICALS LTD., ) )
Defendants. ORDER THIS MATTER having been moved, jointly, by attorneys for Plaintiff Novartis Pharmaceuticals Corporation (“Novartis”) and Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. (collectively, “Torrent”), and the Court having considered all papers submitted in support of this motion and for good cause shown;
The Court hereby vacates the following orders entered on the docket in MDL No. 20- 2930-RGA and Civil Action No. 19-1979-RGA as applicable to Novartis’s claims against Torrent: (1) the July 7, 2023 opinion invalidating U.S. Patent No. 8,101,659 (“the ’659 Patent”) (MDL No. 20-2930-RGA, D.I. 1099; C.A. No. 19-1979-RGA, D.I. 646), and (2) the July 21, 2023 ’659 Patent Judgment (MDL No. 20-2930-RGA, D.I. 1120; C.A. No. 19-1979-RGA, D.I. 649).
1 ME1 49537295v.1
Case 1:20-md-02930-RGA Document 1512 Filed 08/23/24 Page 2 of 2 PageID #: 52474
IT IS SO ORDERED. /s/ Richard G. Andrews August 23, 2024
Dated: _______________ United States District Judge 2 ME1 49537295v.1